Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Fighting Addictions, improving Lives: COmprehensive drug rehabilitation with music

Project description

Innovative therapies for substance use disorder recovery

Substance use disorder is a pervasive health issue, contributing to 5.4 % of all disability-adjusted life years lost globally due to alcohol and illicit drugs. Its complex multimorbidity, including polysubstance use and mental health conditions, presents significant treatment challenges. While music therapy shows promise in enhancing motivation and reducing craving, its long-term effects remain unclear. Addressing this gap, the EU-funded FALCO project consortium is conducting a multinational clinical trial with 600 participants to assess the efficacy of active music and listening groups compared to standard treatment. FALCO aims to revolutionise SUD care with innovative, cost-effective therapies, improving recovery outcomes and quality of life across Europe.

Objective

Objectives and ambition: Substance use disorder (SUD) is associated with a high global burden of disease, with 5.4% of all disability-adjusted life years lost due to alcohol and illicit drugs. Highly prevalent multimorbidity includes polysubstance use, mental health conditions, and other non-communicable and infectious diseases. Where traditional treatments are insufficient alone, music therapy (MT) is highly engaging and improves motivation and craving, but its long-term effects are unknown.
Methodology: In a diverse group of people with SUD across a wide range of age, gender, socioeconomic, and cultural background, a parallel 3-arm assessor-blinded pragmatic multinational randomised clinical trial with embedded exploratory trials and mechanistic studies will determine long-term effects of active music groups (AMG) and music listening groups (MLG) versus treatment as usual (TAU) on addiction severity (primary: 1 year), recovery, and other health and socioeconomic outcomes. Embedded trials will examine short-term effects of individual components of TAU combined with AMG or MLG to determine the best combinations of interventions. Experimental studies will examine mechanisms using neuropsychological tests and brain imaging. With 600 participants in 7 countries randomised, the trial has 80% power on the primary outcome. Patient representatives, HTA bodies, and interventionists have been involved from conception and will ensure feasibility and applicability across Europe.
Impact: FALCO will reduce disease burden through innovative, effective, and affordable treatment and will strengthen research and innovation expertise. Recommendations from FALCO will inform intervention delivery across Europe and beyond, leading to increased safety, effectiveness and cost-effectiveness, and improved quality of life for people with SUD. Stakeholders will be involved in communicating findings in all European countries and regions and ensuring that findings are effectively implemented.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-DISEASE-03-two-stage

See all projects funded under this call

Coordinator

NORCE RESEARCH AS
Net EU contribution
€ 1 804 758,34
Address
NYGARDSGATEN 112
5838 BERGEN
Norway
Region
Norge Vestlandet Vestland
Activity type
Research Organisations
Links
Total cost
No data

Participants (17)

Partners (1)